Results for tag: "Hodgkin Lymphoma Drug"

Hodgkin Lymphoma (HL) is a type of cancer that affects the lymphatic system. Treatment for HL typically involves chemotherapy, radiation therapy, and/or stem cell transplantation. Drug therapy is an important part of the treatment regimen for HL, and there are a variety of drugs available to treat the disease. These drugs can be divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific molecules or pathways in the cancer cells, while immunotherapies are designed to stimulate the body's own immune system to fight the cancer. The Hodgkin Lymphoma Drug market is a rapidly growing segment of the larger Lymphoma Drugs market. The market is driven by the increasing prevalence of HL, advances in drug development, and the availability of new treatments. The market is expected to continue to grow in the coming years as new treatments become available and the demand for more effective treatments increases. Some of the major companies in the Hodgkin Lymphoma Drug market include AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more